|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10 Pt 2
|
|
pubmed:dateCreated |
2003-9-24
|
|
pubmed:abstractText |
Pharmacokinetics and dosimetry of hMN-14 x m734 bispecific monoclonal antibody (BsMAb) and (131)I-labeled di-diethylenetriaminepentaacetic acid-indium ((131)I-hapten) were studied to optimize pretargeted radioimmunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BarbetJacquesJ,
pubmed-author:BardièsManuelM,
pubmed-author:BrardPierre-YvesPY,
pubmed-author:ChangKenK,
pubmed-author:ChatalJean-FrançoisJF,
pubmed-author:DevillersAnneA,
pubmed-author:Faivre-ChauvetAlainA,
pubmed-author:FerrerLudovicL,
pubmed-author:GoldenbergDavid MDM,
pubmed-author:Kraeber-BodéréFrançoiseF,
pubmed-author:LaffontSophieS,
pubmed-author:RescheIsabelleI,
pubmed-author:RothH WHW,
pubmed-author:SharkeyRobert MRM,
pubmed-author:VuillezJean-PhilippeJP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3973S-81S
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14506196-Adult,
pubmed-meshheading:14506196-Aged,
pubmed-meshheading:14506196-Antibodies, Bispecific,
pubmed-meshheading:14506196-Bone Marrow,
pubmed-meshheading:14506196-Carcinoembryonic Antigen,
pubmed-meshheading:14506196-Female,
pubmed-meshheading:14506196-Haptens,
pubmed-meshheading:14506196-Humans,
pubmed-meshheading:14506196-Iodine Radioisotopes,
pubmed-meshheading:14506196-Male,
pubmed-meshheading:14506196-Middle Aged,
pubmed-meshheading:14506196-Neoplasm Metastasis,
pubmed-meshheading:14506196-Neoplasms,
pubmed-meshheading:14506196-Quality Control,
pubmed-meshheading:14506196-Radioimmunotherapy,
pubmed-meshheading:14506196-Radiometry,
pubmed-meshheading:14506196-Time Factors,
pubmed-meshheading:14506196-Tissue Distribution
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
|
|
pubmed:affiliation |
Nuclear Medicine Department, René Gauducheau Cancer Center, 44805 Saint Herblain, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
